Statera Biopharma (STAB) 10-K 7 Mar 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 05, 2019	Jun. 30, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	CLEVELAND BIOLABS INC
Trading Symbol	CBLI
Entity Central Index Key	1,318,641
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		11,298,239
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 11,633,726

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 3,617,234	$ 4,230,548
Short-term investments	503,810	4,561,357
Accounts receivable	251,846	554,468
Other current assets	103,397	233,617
Total current assets	4,476,287	9,579,990
Equipment, net	27,747	18,588
Other long-term assets	30,373	30,684
Total assets	4,534,407	9,629,262
Current liabilities:
Accounts payable	139,120	201,396
Accrued expenses	694,164	970,547
Accrued warrant liability	78,637	1,041,455
Total current liabilities	911,921	2,213,398
Non-current liabilities	8,459	7,494
Commitments and contingencies (Note 9)	0	0
Total liabilities	920,380	2,220,892
Stockholders’ equity:
Preferred stock, $.005 par value; 1,000,000 shares authorized as of December 31, 2018 and December 31, 2017, 0 shares issued and outstanding as of December 31, 2018 and December 31, 2017	0	0
Common stock, $.005 par value; 25,000,000 shares authorized as of December 31, 2018 and December 31, 2017, 11,298,239 and 11,279,834 shares issued and outstanding as of December 31, 2018 and December 31, 2017, respectively	56,487	56,395
Additional paid-in capital	163,161,523	163,106,400
Accumulated other comprehensive loss	(611,370)	(516,457)
Accumulated deficit	(164,058,585)	(160,446,612)
Total Cleveland BioLabs, Inc. stockholders’ equity (deficit)	(1,451,945)	2,199,726
Noncontrolling interest in stockholders’ equity (deficit)	5,065,972	5,208,644
Total stockholders’ equity	3,614,027	7,408,370
Total liabilities and stockholders’ equity	$ 4,534,407	$ 9,629,262

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value ($ per share)	$ 0.005	$ 0.005
Preferred stock, shares authorized	1,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value ($ per share)	$ 0.005	$ 0.005
Common stock, authorized (shares)	25,000,000	160,000,000
Common stock, issued (shares)	11,298,239	11,279,834
Common stock, outstanding (shares)	11,298,239	11,279,834
Treasury stock, (shares)	0	0

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues:
Grants and contracts	$ 1,138,187	$ 1,948,362
Operating expenses:
Research and development	3,619,103	5,048,423
General and administrative	2,318,990	2,500,749
Total operating expenses	5,938,093	7,549,172
Loss from operations	(4,799,906)	(5,600,810)
Other income (expense):
Interest and other income	126,127	197,766
Foreign exchange gain (loss)	3,514	(13,482)
Change in value of warrant liability	962,818	(4,426,146)
Total other income (expense)	1,092,459	(4,241,862)
Net loss	(3,707,447)	(9,842,672)
Net loss attributable to noncontrolling interests	(95,474)	(136,216)
Net loss attributable to Cleveland BioLabs, Inc.	$ (3,611,973)	$ (9,706,456)
Net loss available to common stockholders per share of common stock, basic and diluted (per share)	$ (0.32)	$ (0.87)
Weighted average number of shares used in calculating net income (loss) per share, basic and diluted (shares)	11,293,842	11,192,435

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Statement of Comprehensive Income [Abstract]
Net loss including noncontrolling interests	$ (3,707,447)	$ (9,842,672)
Other comprehensive income (loss):
Unrealized gain on short-term investments	1,924	362
Foreign currency translation adjustment	(144,035)	69,789
Comprehensive loss including noncontrolling interests	(3,849,558)	(9,772,521)
Comprehensive loss attributable to noncontrolling interests	142,672	114,167
Comprehensive loss attributable to Cleveland BioLabs, Inc.	$ (3,706,886)	$ (9,658,354)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net loss	$ (3,707,447)	$ (9,842,672)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	18,175	21,081
Unrealized currency gain on short-term investments	(31,004)	(54,551)
Gain on equipment disposal	(35,649)	(6,727)
Change in value of warrant liability	(962,818)	4,426,146
Changes in operating assets and liabilities:
Accounts receivable and other current assets	431,324	(144,443)
Other long-term assets	(164)	0
Accounts payable and accrued expenses	(325,832)	(1,010,293)
Net cash used in operating activities	(4,613,415)	(6,611,459)
Cash flows from investing activities:
Purchase of short-term investments	(7,737,132)	(8,631,685)
Sale of short-term investments	11,695,498	12,515,024
Proceeds from sale of equipment	36,145	8,956
Purchase of equipment	(27,877)	(4,404)
Net cash provided by investing activities	3,966,634	3,887,891
Cash flows from financing activities:
Exercise of warrants	55,215	0
Net cash provided by financing activities	55,215	0
Effect of exchange rate change on cash and equivalents	(21,748)	52,300
Decrease in cash and cash equivalents	(613,314)	(2,671,268)
Cash and cash equivalents at beginning of period	4,230,548	6,901,816
Cash and cash equivalents at end of period	3,617,234	4,230,548
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	0	0
Supplemental schedule of non-cash financing activities:
Cashless exercise of warrants	$ 0	$ 4,334,110

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)	Total	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2016		10,987,166	0
Beginning balance at Dec. 31, 2016	$ 12,846,781	$ 54,932	$ 0	$ 158,773,753	$ (564,559)	$ (150,740,156)	$ 5,322,811
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of warrants (in shares)		292,668
Exercise of warrants	4,334,110	$ 1,463		4,332,647
Net loss	(9,842,672)					(9,706,456)	(136,216)
Unrealized gain on short-term investments	362				362
Foreign currency translation	69,789				47,740		22,049
Ending balance (in shares) at Dec. 31, 2017		11,279,834	0
Ending balance at Dec. 31, 2017	7,408,370	$ 56,395	$ 0	163,106,400	(516,457)	(160,446,612)	5,208,644
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of warrants (in shares)		18,405
Exercise of warrants	0	$ 92		55,123
Net loss	(3,707,447)					(3,611,973)	(95,474)
Unrealized gain on short-term investments	1,924				1,924
Foreign currency translation	(144,035)				(96,837)		(47,198)
Ending balance (in shares) at Dec. 31, 2018		11,298,239	0
Ending balance at Dec. 31, 2018	$ 3,614,027	$ 56,487	$ 0	$ 163,161,523	$ (611,370)	$ (164,058,585)	$ 5,065,972

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business Cleveland BioLabs, Inc. (" CBLI " or the " Company ") is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Our proprietary platform of Toll-like immune receptor activators has applications in radiation protection and oncology. We combine our proven scientific expertise and our depth of knowledge about our products’ mechanisms of action into a passion for developing drugs to save lives. Our most advanced product candidate is entolimod, an immune-stimulatory agent, which we are developing as a medical radiation countermeasure and other indications in radiation oncology. CBLI was incorporated in Delaware in June 2003 and is headquartered in Buffalo, New York. CBLI conducts business in the United States (" U.S. ") and in the Russian Federation (" Russia ") through two subsidiaries: one wholly-owned subsidiary, BioLab 612, LLC ( "BioLab 612" ), which began operations in 2012; and Panacela Labs, Inc. (" Panacela "), which was formed by us and Joint Stock Company "RUSNANO" (" Rusnano "), our financial partner in the venture, in 2011. Unless otherwise noted, references to the "Company," "we," "us," and "our" refer to Cleveland BioLabs, Inc. together with its subsidiaries. On August 6, 2018, the Company entered into a series of transactions with Genome Protection, Inc. ("GPI") , a corporation formed by the Company for the purpose of creating a joint venture between the Company and Everon Biosciences, Inc. ("Everon") that would be focused on developing anti-aging medications and would seek investment capital from third parties. On August 6, 2018, the Company entered into a License Agreement with GPI (the "License Agreement" ) pursuant to which the Company licensed to GPI, on an exclusive basis, the right to develop, manufacture, commercialize and sell products utilizing the Company’s intellectual property underlying the Company’s entolimod drug candidate, solely in the field of use related to the prevention or treatment of any disease, disorder or frailty in humans caused by aging. Simultaneous with its entry into the License Agreement, the Company also entered into an Assignment Agreement with GPI (the "Assignment Agreement" ), under which the Company assigned certain intellectual property underlying its GP532 product candidate and its entolimod vaccine product candidate and GPI licensed back to the Company, on an exclusive, irrevocable basis, the right to develop manufacture, commercialize and sell products relating to the assigned intellectual property for use as a medical countermeasure to treat acute radiation exposure or as a cancer treatment. As consideration for the licenses granted to GPI under the License Agreement and the assignment of the intellectual property to GPI under the Assignment Agreement, GPI issued to the Company 1,000 shares of GPI’s common stock. Contemporaneously with the Company’s entry into the License Agreement and Assignment Agreement, Everon contributed certain of its intellectual property related to the potential development of treatments that address serious medical needs associated with human aging to GPI, also in exchange for 1,000 shares of GPI’s common stock. As a result of each of the Company’s and Everon’s receipt of 1,000 shares of GPI’s common stock, each of the Company and Everon became the owner of 50% of all of the outstanding capital stock of GPI. Subsequent to the intellectual property transfers described above, the Company, GPI and Everon entered into agreements with a third-party investor for the purpose of providing GPI with capital. On August 10, 2018, GPI, Norma Investments Limited, a British Virgin Islands company ("Norma") , the Company and Everon entered into a Simple Agreement for Future Equity (the " SAFE" ). Under the SAFE, GPI granted Norma the right to purchase shares of GPI’s capital stock in exchange for the payment of up to $30,000,000 , of which $10,500,000 was paid shortly after the execution of the SAFE and the remainder may be paid, if at all, in tranches over time. Norma may exercise its right to purchase shares of GPI’s capital stock upon the occurrence of certain events, or otherwise may alternatively be paid an amount equal to its investment amount (plus accrued interest, in certain cases). Under the SAFE, the parties agreed that GPI’s board of directors (the " GPI Board" ) will consist of four members, two of whom will be selected by Norma, one of whom will be selected by the Company and one of whom will be selected by Everon. The SAFE also provides that the parties will agree that a quorum of the GPI Board will require that at least one of the directors selected by Norma be present. Additionally, the SAFE sets forth a number of actions that GPI will be prohibited from taking without the unanimous consent of all of the members of the GPI Board and sets forth other matters that must be approved by a majority of the members of the GPI Board. The Company and Everon have each guaranteed, to the extent of their powers as stockholders of GPI, the due and punctual performance by GPI of all of its obligations under the SAFE. In connection with the execution of the SAFE, the Company, Everon, GPI and Norma entered into a Director Designation Agreement, dated as of August 10, 2018, pursuant to which the parties made certain commitments as to voting and transfer of their shares of GPI and GPI’s governance. The Company has accounted for its investment in GPI under the equity method of accounting in the accompanying financial statements. In addition, the Company has not recorded its 50% share of the losses of GPI through December 31, 2018 as the impact would have reduced the Company's equity method investment in GPI below zero, and there are no requirements to fund the Company's share of these losses or contribute additional capital as of the date of these statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation and Consolidation The accompanying consolidated financial statements include the accounts of CBLI, BioLab 612, and Panacela. All significant intercompany balances and transactions have been eliminated in consolidation. These financial statements have been prepared on the accrual basis in accordance with accounting principles generally accepted in the United States (" GAAP "). At December 31, 2018, we had cash, cash equivalents, and short-term investments of $4.1 million . Of that total, $0.5 million was restricted for the use of our consolidated joint venture, Panacela, leaving $3.6 million available for general use, which management believes will be sufficient to support operations into December 2019. To ensure continuing operations beyond that point, management is evaluating all opportunities to secure additional financing, including investments from non-controlling interests, the sale or license of our drug candidates, the issuance of equity and securing additional revenues from the U.S. or Russian governments. Management believes that sufficient sources of financing will be available to support operations into the future, however there can be no assurances at this time. These matters raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements have been prepared under the assumption that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents Of the $3.6 million and $4.2 million of cash and cash equivalents at December 31, 2018 and December 31, 2017 , respectively, $0.0 million and $3.6 million , respectively, consisted of highly liquid investments with maturities of 90 days or less when purchased. These investments consist of investments in money market funds with commercial banks and financial institutions. As of December 31, 2018 , $147,400 of the Company’s cash and cash equivalents were held in Russian banks, of which $136,200 was denominated in rubles with the remaining $11,200 denominated in U.S. dollars. Short-Term Investments The Company’s short-term investments are classified as and held to maturity and recorded at amortized cost. Short-term investments consist of $0.5 million in certificates of deposit with maturity dates beyond three months and less than one year and are owned by Panacela. These investments are classified as held to maturity given the intent and ability to hold the investments to maturity. Realized gains and losses, and interest and dividends on short-term investments are recorded in our Consolidated Statement of Operations as Interest and Other Income. The cost of securities sold is based on the specific identification method. Concentrations of Credit Risk Financial instruments that potentially subject the Company to a significant concentration of credit risk primarily consist of cash and cash equivalents and short-term investments. The Company maintains cash balances with financial institutions in excess of insured limits. As of December 31, 2018 , the Company held 4% of its cash and cash equivalents in accounts located outside of the United States. As of February 7, 2019 , the Dollar:Russian Ruble exchange rate increased to 65.6686 , resulting in a decrease of $8.5 thousand to the Company’s cash and cash equivalents as compared to December 31, 2018 . Significant Customers and Accounts Receivable The following table presents our revenue by customer, on a proportional basis, for the periods indicated: Years ended December 31, 2018 2017 Variance U.S. Department of Defense 46.3 % 69.0 % (22.7 )% Incuron, LLC 53.7 % 31.0 % 22.7 % 100.0 % 100.0 % — % Although the Company anticipates ongoing contract and grant revenue from these customers, there is no guarantee that these revenue streams will continue in the future. The Company extends unsecured credit to its government customers under normal trade agreements and contracted terms, which generally require payment within 30 days . Accounts receivable consist of amounts due under contracts and grants from these customers, along with amounts receivable under subleases at our Buffalo, New York office facility. There were allowances for doubtful accounts of $0.2 million and $0.2 million at December 31, 2018 and December 31, 2017 , respectively, pertaining to accounts receivable from our subleases. Equipment Equipment is stated at cost, net of accumulated depreciation. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repair and maintenance costs are expensed as incurred. Equipment is depreciated using the straight-line method over the estimated useful lives of the respective assets as follows: Asset Category Estimated Useful Life (in Years) Laboratory equipment 5 Furniture and fixtures 5 Computer equipment 3 Impairment of Long-Lived Assets Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets or related asset group may not be recoverable. Determination of recoverability is based on an estimate of discounted future cash flows resulting from the use of the asset. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the carrying amount of the asset is written down to its estimated net realizable value. Intellectual Property Costs related to filing and pursuing patent applications are recognized as general and administrative expenses as incurred, since the recoverability of such expenditures is uncertain. Upon marketability approval by the FDA, or a respective foreign regulatory governing body, such costs will be capitalized and depreciated over the expected life of the related patent. Accrued Warrant Liability Certain warrants are accounted for as derivative instruments in accordance with the Financial Accounting Standards Board Accounting Standards Codification (the " Codification ") on derivatives and hedging as the warrant holders, under certain change of control situations, could require settlement in cash. As such, the warrants were initially recorded as liabilities based on their fair values on the date of issuance. Subsequent changes in the value of the warrants are recorded in the Statements of Operations as "Change in value of warrant liability." The Company’s remaining outstanding warrants were treated as equity upon issuance and continue to be treated as equity since they did not contain any mandatory redemption features or other provisions that would require a different classification of these warrant instruments outside of permanent equity. Foreign Currency Translation The Russian ruble is the functional currency of our foreign subsidiaries, which are all located in the Russian Federation. Assets and liabilities of these companies are translated into U.S. dollars at the period-end exchange rate. Income and expense items are translated at the average exchange rates during the period. The net effect of this translation is recorded in the consolidated financial statements as accumulated other comprehensive income (loss). Other Comprehensive Income (Loss) The Company applies the Accounting Standards Codification ( "Codification" ) on comprehensive income (loss) that requires disclosure of all components of comprehensive income (loss) on an annual and interim basis. Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The following table presents the changes in accumulated other comprehensive loss for the year ended December 31, 2018 . Unrealized gain (loss) on available-for-sale securities Gains and losses on foreign exchange translations Total Beginning balance $ (1,924 ) $ (514,533 ) $ (516,457 ) Other comprehensive income (loss) before reclassifications 1,924 (96,837 ) (94,913 ) Ending balance $ — $ (611,370 ) $ (611,370 ) Revenue Recognition The Company generates grant and contract revenue from two different types of contractual arrangements: cost reimbursable grants and contracts, and fixed-price grants and contracts. Costs consist primarily of internal labor charges, subcontractors and materials, as well as an allocation of fringe benefits, overhead and general and administrative expenses, based on the terms of the contract. Under cost reimbursable grants and contracts, revenue is recognized during the period that the associated research and development costs are incurred. Under fixed-price grants and contracts, revenue is recognized using the percentage-of-completion method. The assumptions and estimates used in determination of the percentage-of-completion are developed in coordination with the principal investigator performing the work. Research and Development Research and development (" R&D ") costs are expensed as incurred. R&D costs primarily consist of salaries, fringe benefits, and stock-based compensation for our clinical and scientific personnel along with a ratable share of our facility expenses. Other R&D expenses include fees paid to research-oriented consultants and outside service providers, and the costs of materials used in clinical trials and other research activities. Accounting for Stock-Based Compensation The Cleveland BioLabs, Inc. Equity Incentive Plan, adopted in 2018 (the " Plan" ), authorizes CBLI to grant (i) options to purchase common stock, (ii) restricted or unrestricted stock units, and (iii) stock appreciation rights, so long as the exercise or grant price of each are at least equal to the fair market value of the stock on the date of grant. As of December 31, 2018 , an aggregate of 597,557 shares of common stock were authorized for issuance under the Plan, of which a total of approximately 437,481 shares of common stock remained available for future awards. In addition, a total of 160,076 shares of common stock reserved for issuance were subject to currently outstanding stock options granted under the Plan, as in effect prior to the 2018 amendment and restatement. A single participant cannot be awarded more than 100,000 shares annually. Awards granted under the Plan have a contractual life of no more than 10 years . The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Plan are specified in an award document, and approved by the Company's board of directors or its management delegates. The 2013 Employee Stock Purchase Plan (" ESPP ") provides a means by which eligible employees of the Company and certain designated related corporations may be given an opportunity to purchase shares of common stock. As of December 31, 2018 , there were 525,000 shares of common stock reserved for purchase under the ESPP. The number of shares reserved for purchase under the ESPP increases on January 1 of each calendar year by the lesser of (i) 10% of the total number of shares of common stock outstanding on December 31st of the preceding year, or (ii) 100,000 shares of common stock. The ESPP allows employees to use up to 15% of their compensation to purchase shares of common stock at an amount equal to 85% of the fair market value of the Company's common stock on the offering date or the purchase date, whichever is less. The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted where the vesting period is based on length of service or performance, while a Monte Carlo simulation model is used for estimating the fair value of stock options with market-based vesting conditions. No options were granted during the years ended December 31, 2018 and 2017. Income taxes No income tax expense was recorded for the years ended December 31, 2018 and 2017 as the Company did not have taxable income for any of the years presented. A full valuation allowance has been recorded against the Company’s net deferred tax asset. Earnings (Loss) per Share Basic net loss per share of common stock excludes dilution for potential common stock issuances and is computed by dividing net loss by the weighted average number of shares outstanding for the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Diluted net loss per share is identical to basic net loss per share as potentially dilutive securities have been excluded from the calculation of diluted net loss per common share because the inclusion of such securities would be antidilutive. The Company has excluded the following securities from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented: As of December 31, Common Equivalent Securities 2018 2017 Warrants 528,054 710,174 Options 160,076 211,487 Total 688,130 921,661 Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ( "FASB" ) or other standard-setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. In May 2017, the FASB issued Accounting Standards Update (" ASU ") No. 2017-09, "Scope of Modification Accounting" (" ASU No. 2017-09 "), which amends the scope of modification accounting for share-based payment arrangements.The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting. ASU 2017-09 is applied prospectively to awards modified on or after the effective date. The Company adopted this ASU in 2018 with no significant impact on its consolidated financial statements. In November 2016, the FASB issued ASU 2016-18, "Statement of Cash Flows (Topic 230): Restricted Cash" (" ASU 2016-18" ). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The Company adopted this ASU in 2018 with no significant impact on its consolidated financial statements. In May 2014, the FASB issued ASU 2014-9, "Revenue from Contracts with Customers" ( "ASU 2014-09" ), which updates the principles for recognizing revenue. ASU 2014-9 also amends the required disclosures of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company adopted this ASU in 2018 with no significant impact on its consolidated financial statements. In May 2016, the FASB issued ASU 2016-12, "Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients" ( "ASU 2016-12" ). The amendments in ASU 2016-12 affect the guidance in ASU 2014-09 by clarifying certain specific aspects of the guidance, including assessment of collectability, treatment of sales taxes and contract modifications, and providing certain technical corrections. The pronouncement has the same effective date as ASU 2014-09, which is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017. The Company adopted this ASU in 2018 with no significant impact on its consolidated financial statements. In August 2016, the FASB issued ASU 2016-10, "Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing" (" ASU 2016-10" ) related to identifying performance obligations and licensing. ASU 2016-10 is meant to clarify the guidance in FASB ASU 2014-09, "Revenue from Contracts with Customers." Specifically, ASU 2016-10 addresses and entity's identification of its performance obligations in a contract, as well as an entity's evaluation of the nature of its promise to grant a license of intellectual property and whether or not that revenue is recognized over time or at a point in time. The pronouncement has the same effective date as ASU 201-09, which is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017. The Company expects to adopt this guidance when effective and is currently evaluating the effect that the updated standard will have on its consolidated balance sheets and related disclosures. The Company adopted this ASU in 2018 with no significant impact on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, "Leases (Topic 842)" (" ASU 2016-02" ). ASU 2016-02 will require organizations that lease assets with lease terms of more than 12 months to recognize assets and liabilities for the rights and obligations created by those leases on their balance sheets. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 will be effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company adopted this ASU in 2019 with no significant impact on its consolidated financial statements. In January 2016, the FASB issued ASU 2016-01, "Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities" (" ASU 2016-01" ). The pronouncement requires equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income, requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes, requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset, and eliminates the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost. The Company adopted this ASU in 2018 with no significant impact on its consolidated financial statements. Reclassification In order to facilitate comparison of financial information, certain amounts reported in the prior year have been reclassified to conform to the current year presentation.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company measures and records warrant liabilities at fair value in the accompanying financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, includes: • Level 1 – Observable inputs for identical assets or liabilities such as quoted prices in active markets; • Level 2 – Inputs other than quoted prices in active markets that are either directly or indirectly observable; and • Level 3 – Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use. The following tables represent the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2018 and 2017 : As of December 31, 2018 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents $ 1,130 $ — $ — $ 1,130 Short-term investments — 503,810 — 503,810 Total assets $ 1,130 $ 503,810 $ — $ 504,940 Liabilities: Accrued warrant liability $ — $ — $ 78,637 $ 78,637 As of December 31, 2017 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents $ 551,088 $ — $ — $ 551,088 Short-term investments 3,606,499 954,858 — 4,561,357 Total assets $ 4,157,587 $ 954,858 $ — $ 5,112,445 Liabilities: Accrued warrant liability $ — $ — $ 1,041,455 $ 1,041,455 The Company has certain warrants that could require settlement in cash if a fundamental transaction occurs, as defined in the respective agreements. These agreements specify the amount due to warrant holders is based on the Black-Scholes pricing model. The following are the assumptions used to measure the accrued warrant liability at December 31, 2018 and 2017 : "Risk-free interest rate" means the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date the option is granted. "Expected dividend yield" means the anticipated dividend return for an investor over the expected life. For the Company, this amount is zero as it is not anticipated that dividends will be paid for the foreseeable future. "Expected life" means the period of time that options granted are expected to remain outstanding, based wholly on the use of the simplified (safe harbor) method. The simplified method is used because the Company does not yet have adequate historical exercise information to estimate the expected life the options granted. "Expected volatility" means a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. Expected volatility is based on the Company’s historical volatility and incorporates the volatility of the common stock of comparable companies when the expected life of the option exceeds the Company’s trading history. December 31, 2018 2017 Stock Price $ 1.01 $ 4.01 Exercise Price $ 3.64 - 24.40 $ 3.00 - 24.40 Term in years 0.04 - 2.60 0.25 - 3.60 Volatility 88.07 - 108.18% 71.48 - 139.58% Annual rate of quarterly dividends 0 % 0 % Discount rate- bond equivalent yield 0.12 - 2.48% 0.44 - 2.05% The following table sets forth a summary of changes in the fair value of the Company’s Level 3 fair value measurement of the accrued warrant liability for the years ended December 31, 2018 and 2017 : Year Ended December 31, 2018 Beginning Balance $ 1,041,455 Total (gains) or losses, realized and unrealized, included in earnings (1) (962,818 ) Balance at December 31, 2018 $ 78,637 Year Ended December 31, 2017 Beginning Balance $ 949,419 Total (gains) or losses, realized and unrealized, included in earnings (1) 4,426,146 Settlements (4,334,110 ) Balance at December 31, 2017 $ 1,041,455 (1) Unrealized gains or losses related to the accrued warrant liability were included as change in value of accrued warrant liability. Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis, as documented above, from those measured at fair value on a nonrecurring basis. As of December 31, 2018 and 2017 , the Company had no assets or liabilities that were measured at fair value on a nonrecurring basis. The Company considers the accrued warrant liability measurement to be Level 3 because some of the inputs into the measurements are neither directly or indirectly observable. The following table summarizes the unobservable inputs into the fair value measurements: December 31, 2018 Description Fair Value Valuation Technique Unobservable Input Range in years Accrued warrant liability $ 78,637 Black-scholes pricing model Expected term 0.04 - 2.60 Management believes the value of the accrued warrant liability is more sensitive to changes in the Company’s stock price at the end of the respective reporting period as opposed to changes in the expected term. At December 31, 2018 , a 10% increase in the expected term of the Company’s warrants measured using the Black-Scholes pricing model would increase the warrant liability by approximately 6% , while a 10% decrease in the expected term would decrease the warrant liability by approximately 6% . A 10% increase in the Company’s stock price would result in an increase in the accrued warrant liability of approximately 17% , while a 10% decrease in the stock price would decrease the warrant liability by approximately 16% . The carrying amounts of the Company’s remaining financial instruments, which include cash, short-term investments, accounts receivable and accounts payable, approximate their fair values due to their short maturities.

Equipment

Equipment	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Equipment	Equipment The following table summarizes the value of the Company’s equipment as of December 31, 2018 and 2017 : As of December 31, 2018 2017 Computer equipment $ 186,456 $ 208,943 Lab equipment 448,198 554,880 Furniture 500,201 500,202 1,134,855 1,264,025 Less accumulated depreciation (1,107,108 ) (1,245,437 ) Equipment, net $ 27,747 $ 18,588

Equity Awards

Equity Awards	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Equity Awards	Warrants In connection with sales of the Company's common stock and the issuance of debt instruments that have since been repaid, warrants were issued. The warrants expire between one and seven years from issuance from the date of grant and are subject to the terms applicable in each agreement. The following table sets forth the changes in the number of warrants outstanding for the periods presented: Number of Warrants Weighted Average Exercise Price Outstanding at December 31, 2016 2,148,741 $ 11.04 Exercised (1,181,235 ) 3.64 Forfeited, Canceled (257,332 ) 50.76 Outstanding at December 31, 2017 710,174 8.95 Exercised (18,405 ) 3.00 Forfeited, Canceled (163,715 ) 3.34 Outstanding at December 31, 2018 528,054 $ 10.90 During April 2017, warrant holders exercised 1,181,235 warrants for 292,668 shares of the Company's common stock through cashless exercise. The fair value of the warrants exercised was valued using the Black Scholes option pricing model based on the following assumptions: Stock Price $ 4.84 Exercise Price $ 3.64 Term in years 4.29 Volatility 101.93 % Annual rate of quarterly dividends 0 % Discount rate- bond equivalent yield 1.65 % Equity Incentive Plan The following is a summary of option award activity under the Plan for the year ended December 31, 2018 : Year Ended December 31, 2018 Total Stock Options Outstanding Weighted Average Exercise Price per Share Nonvested Stock Options Weighted Average Grant Date Fair Value per Share December 31, 2017 211,487 $ 36.94 — $ — Forfeited, Canceled (51,411 ) 40.12 — — December 31, 2018 160,076 $ 35.92 — $ — The following is a summary of outstanding stock options under the Plan as of December 31, 2018 : Stock Options Outstanding Vested Stock Options Quantity 160,076 160,076 Weighted-average exercise price $ 35.92 $ 35.92 Weighted Average Remaining Contractual Term (in Years) 4.26 4.26 Intrinsic value $ — $ — For the years ended December 31, 2018 and 2017 , the Company granted no stock options. For the years ended December 31, 2018 and 2017 , the total fair value of options vested was $0 . The total intrinsic value of options exercised for the years ended December 31, 2018 and 2017 was $0 . As of December 31, 2018 , there was no total compensation cost not yet recognized related to unvested stock options.

Significant Alliances and Relat

Significant Alliances and Related Parties	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Significant Alliances and Related Parties	Significant Alliances and Related Parties Roswell Park Cancer Institute The Company has entered into several agreements with Roswell Park Cancer Institute (" RPCI "), including: various sponsored research agreements, an exclusive license agreement and clinical trial agreements for the conduct of the Phase 1 entolimod oncology study and the Phase 1 CBL0137 intravenous administration study. Additionally, the Company’s Chief Scientific Officer, Dr. Andrei Gudkov, is the Senior Vice President of Basic Research at RPCI. The Company incurred $200,455 and $55,299 in expense to RPCI related to research grants and agreements for the years ended December 31, 2018 and 2017 , respectively. The Company had $0 and $8,391 included in accounts payable owed to RPCI at December 31, 2018 and 2017 , respectively. In addition, the Company had $0 and $84,429 in accrued expenses payable to RPCI at December 31, 2018 and 2017 , respectively. The Cleveland Clinic CBLI entered into an exclusive license agreement, or the License, with The Cleveland Clinic (" CCF "), pursuant to which CBLI was granted an exclusive license to The Cleveland Clinic’s research base underlying our therapeutic platform and certain product candidates in development by Panacela. CBLI has the primary responsibility to fund all newly developed patents; however, CCF retains ownership of those patents covered by the agreement. CBLI also agreed to use commercially diligent efforts to bring one or more products to market as soon as practical, consistent with sound and reasonable business practices and judgments. In consideration for the License, CBLI agreed to issue CCF common stock and make certain milestone, royalty and sublicense royalty payments. Milestone payments, which may be credited against future royalties, amounted to $0 for the years ended December 31, 2018 and 2017 . No royalty or sublicense royalty payments were made to CCF during the two -year period ended December 31, 2018 . The Company also recognized $41,484 and $11,700 as research and development expense to CCF for the years ended December 31, 2018 and 2017 , respectively. The Company had $0 and $11,700 included in accrued expenses payable at December 31, 2018 and 2017 , respectively. Buffalo BioLabs and Incuron Our Chief Scientific Officer, Dr. Andrei Gudkov, has business relationships with several entities with which we transact business, the most significant of which is Buffalo BioLabs (" BBL "), where Dr. Gudkov was a founder and currently serves as its Principal Scientific Adviser. Pursuant to a master services agreement we have with BBL, the Company recognized $454,937 and $197,900 as research and development expense to BBL for the years ended December 31, 2018 and 2017 , respectively, and included $28,000 and $0 in accounts payable to BBL at December 31, 2018 and 2017 , respectively. In addition, the Company had $ 0 and $13,889 in accrued expenses payable to BBL at December 31, 2018 and 2017 , respectively. We also recognized $46,212 and $42,361 from BBL for sublease and other income for the years ended December 31, 2018 and 2017 , respectively. Pursuant to our real estate sublease and equipment lease with BBL, we had gross and net accounts receivable of $218,300 and $ 16,149 from BBL at December 31, 2018 , respectively, and gross and net accounts receivables of $202,151 and $ 0 from BBL at December 31, 2017 , respectively. Dr. Gudkov is also an uncompensated member of the board of directors for Incuron. Pursuant to master service and development agreements we have with Incuron, the Company performs various research, business development, clinical advisory, and management services. We recognized revenue of $610,907 and $604,010 from Incuron for the years ended December 31, 2018 and 2017 , respectively. In addition, we also recognized $5,107 and $7,104 from Incuron for sublease and other income for the years ended December 31, 2018 and 2017 , respectively. Pursuant to these agreements, we had gross accounts receivable of $33,316 and $158,651 at December 31, 2018 and 2017 , respectively. Exacte Labs, LLC Our majority owned subsidiary's Chief Executive Officer also serves as the Chief Executive Officer of Exacte Labs, LLC, a Contract Research Organization (" CRO ") with which BioLab 612 transacted business during 2017. BioLab 612 incurred $0 and $11,447 in expense to Exacte Labs for the years ended December 31, 2018 and 2017 , respectively. IP Bayramov Roman Our wholly owned subsidiary's Chief Executive Officer also provides accounting services through a separate legal entity to Panacela Labs, LLC. Professional fee expense to this firm, IP Bayramov Roman, amounted to $19,219 and $13,719 for the years ended December 31, 2018 and 2017 , respectively. Genome Protection The Company has entered into several agreements with GPI. The Company recognized $1,725 in sublease and other income from GPI for the year ended December 31, 2018.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method. Deferred taxes are determined by calculating the future tax consequences attributable to differences between the financial accounting and tax bases of existing assets and liabilities. A valuation allowance is recorded against deferred tax assets when, in the opinion of management, it is more likely than not that the Company will not be able to realize the benefit from its deferred tax assets. The Company files income tax returns, as prescribed by the national, state and local jurisdictions in which it operates. The Company’s uncertain tax positions are related to tax years that remain subject to examination and are recognized in the financial statements when the recognition threshold and measurement attributes are met. Interest and penalties related to tax deficiencies and uncertain tax positions are recorded as income tax expense. Income (loss) from continuing operations consists of the following: For the Year Ended December 31, 2018 2017 US operations $ (3,345,925 ) $ (9,315,082 ) Foreign operations (361,522 ) (527,590 ) $ (3,707,447 ) $ (9,842,672 ) The provision for income taxes charged to continuing operations is $0 for all periods presented. Deferred tax assets (liabilities) were comprised of the following as of the periods presented below: As of December 31, 2018 2017 Deferred tax assets: Operating loss carryforwards $ 35,706,000 $ 34,427,000 Accrued expenses 5,953,000 5,969,000 Tax credit carryforwards 3,951,000 3,864,000 Intellectual property 3,996,000 3,878,000 Equipment 110,000 150,000 Total deferred tax assets 49,716,000 48,288,000 Deferred tax liabilities: — — Net deferred tax asset 49,716,000 48,288,000 Valuation allowance (49,716,000 ) (48,288,000 ) $ — $ — The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. statutory federal income tax rate of 21% for the year ended December 31, 2018 and 34% for the year ended December 31, 2017, to the pretax loss from continuing operations as a result of the following differences: For the Year Ended December 31, 2018 2017 Tax at the U.S. statutory rate $ (779,000 ) $ (3,347,000 ) Change in value of warrant liability (202,000 ) 1,505,000 Valuation allowance 981,000 1,841,000 Other — 1,000 $ — $ — At December 31, 2018 , the Company had U.S. federal net operating loss carryforwards of approximately $144.0 million , of which $139.7 million begins to expire if not utilized by 2023 , and $4.3 million , which has no expiration, and approximately $4,156,000 of tax credit carryforwards which begin to expire if not utilized by 2024. The Company also has state net operating loss carryforwards of approximately $89.8 million , which begin to expire if not utilized by 2027 and state tax credit carryforwards of approximately $304,000 , which begin to expire if not utilized by 2022 . The purchase of 6,459,948 shares of common stock by Mr. Davidovich on July 9, 2015 resulted in Mr. Davidovich owning 60.2% of the Company, at that time. We therefore believe it highly likely that this transaction will be viewed by the U.S. Internal Revenue Service as a change of ownership as defined by Section 382 of the Internal Revenue Code. Consequently, our ability to utilize approximately $124.8 million of U.S. federal net operating loss carryforwards, $3.65 million of U.S. tax credit carryforwards, approximately $73.4 million of state net operating loss carryforwards, and $324,000 of state tax credit carryforwards, all of which occurred prior to July 9, 2015, are limited. As such, a significant portion of these carryforwards will likely expire before they can be utilized, even if the Company is able to generate taxable income that, except for this transaction, would have been sufficient to fully utilize these carryforwards. ASC 740 requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of a deferred tax asset is dependent upon the generation of future taxable income during the periods in which those temporary differences are deductible. In making this determination, management considers all available positive and negative evidence affecting specific deferred tax assets, including the Company's past and anticipated future performance, the reversal of deferred tax liabilities, length of carry-back and carry-forward periods and the implementation of tax planning strategies. Based on all available evidence, management has determined that a full valuation allowance was necessary at December 31, 2018 and 2017. The Company files U.S. federal income tax returns, along with various state and foreign income tax returns. All federal, state and foreign tax returns for the years ended December 31, 2017 , 2016 and 2015 are still open for examination. The following presents a roll-forward of the unrecognized tax benefits and the associated interest and penalties: Unrecognized Tax Benefits Interest and Penalties Balance at January 1, 2017 $ 482,000 $ — Deferred tax position 11,000 — Balance at December 31, 2017 493,000 — Deferred tax position 11,000 — Balance at December 31, 2018 $ 504,000 $ — The U.S. government enacted the Tax Cuts and Jobs Act (the "Tax Act" ) on December 22, 2017, which made several changes to U.S. tax laws that could have a significant impact on the Company. Most of these provisions are effective for tax years beginning after December 31, 2017, and include, but are not limited to, (1) a reduction in the corporate tax rate from 34% to 21%, (2) limitations on the utilization of operating loss carryforwards generated after 2017, (3) limitations on the utilization of interest deductions, (4) requiring a one-time transition tax on undistributed earnings of foreign subsidiaries, (5) elimination of U.S. taxes on dividends received from foreign subsidiaries, (6) implementing a base erosion tax, and (7) implementing a new provision designed to tax currently in the U.S. global intangible low-taxed income (" GILTI ") of foreign subsidiaries. U.S. GAAP requires the impact of tax legislation to be recorded in the period of enactment. Accordingly, the Company's deferred tax assets at December 31, 2017 were reduced by approximately $21.5 million to reflect the lower tax rate that will apply going forward, however, there was no income tax expense given the existence of a full valuation allowance recorded against the deferred tax assets. None of the Company's foreign subsidiaries have undistributed earnings, so there is no impact associated with the one-time transition tax. Going forward, a tax liability could exist under the new GILTI provisions, but that will not apply until the foreign subsidiaries begin to generate income. The timing and amount of income to be generated by the foreign subsidiaries, and the impact of the new GILTI provision is impossible to estimate at this time, and therefore, no impact has been recorded.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2018
Retirement Benefits [Abstract]
Employee Benefit Plan	Employee Benefit Plan CBLI maintains an active defined contribution retirement plan for its employees, referred to herein as the Benefit Plan. All employees satisfying certain service requirements are eligible to participate in the Benefit Plan. The Company makes matching cash contributions each payroll period, up to 4% of employees’ salaries. The Company’s expense relating to the Benefit Plan was $39,794 , and $40,962 for the years ended December 31, 2018 , and 2017 , respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies The Company has entered into various agreements with third parties and certain related parties in connection with the research and development activities of its existing product candidates as well as discovery efforts on potential new product candidates. These agreements include fixed obligations to sponsor research and development activities, make minimum royalty payments for licensed patents and pay additional amounts that may be required upon the achievement of scientific, regulatory and commercial milestones, including milestones such as the submission of an IND to the FDA and the first commercial sale of the Company’s products in various countries. As of December 31, 2018 the Company is uncertain as to whether any of these contingent events will become realized. There were no milestone payments or royalties on net sales accrued for any of these agreements as of December 31, 2018 and 2017 . From time-to-time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues for liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. For all periods presented, other than as set forth below, the Company was not a party to any pending material litigation or other material legal proceedings. On October 22, 2018, the MPT filed a complaint against BioLab 612, one of our subsidiaries operating in the Russian Federation, in the Arbitration court of Moscow city. The complaint alleges that BioLab 612 breached its 2012 and 2013 contracts with the MPT by completing its third stage of the 502 clinical study and seventh stage of the 612 clinical study in an untimely manner. The MPT sought 19,819,281 rubles (or approximately $0.3 million ) in damages and penalties for breach of the 502 contract and 49,519,600 rubles (or approximately $0.75 million ) in damages and penalties for breach of the 612 contract. In November 2018, the court dismissed the claim for damages and penalties arising from the alleged breach of the 502 contract. In January 2019, the court ordered BioLab 612 to pay 2,823,377 rubles (or approximately $0.04 million ) in damages and penalties for breach of the 612 contract. The MPT had until February 19, 2019 to appeal this decision and to our knowledge has not. The Company has entered into agreements with substantially all of our employees who, if terminated by the Company without cause as described in these agreements, would be entitled to severance pay. As of December 31, 2018 , the Company had unconditional purchase obligations totaling $94,456 for goods and services, substantially all of which the Company anticipates to incur during 2019 . Operating Leases The Company leases laboratory facilities and office facilities at various locations with expiration dates through 2019 . The Company recognizes rent expense on a straight-line basis over the term of the related operating leases. For the years ended December 31, 2018 and 2017 , total rent expense related to the Company’s operating leases was $398,346 and $401,455 , respectively. In addition, the Company has subleased some of its facilities. As of December 31, 2018 , future minimum payments under operating leases are as follows: 2019 $ 198,039 Total minimum lease payments $ 198,039

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation The accompanying consolidated financial statements include the accounts of CBLI, BioLab 612, and Panacela. All significant intercompany balances and transactions have been eliminated in consolidation. These financial statements have been prepared on the accrual basis in accordance with accounting principles generally accepted in the United States (" GAAP "). At December 31, 2018, we had cash, cash equivalents, and short-term investments of $4.1 million . Of that total, $0.5 million was restricted for the use of our consolidated joint venture, Panacela, leaving $3.6 million available for general use, which management believes will be sufficient to support operations into December 2019. To ensure continuing operations beyond that point, management is evaluating all opportunities to secure additional financing, including investments from non-controlling interests, the sale or license of our drug candidates, the issuance of equity and securing additional revenues from the U.S. or Russian governments. Management believes that sufficient sources of financing will be available to support operations into the future, however there can be no assurances at this time. These matters raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements have been prepared under the assumption that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents Of the $3.6 million and $4.2 million of cash and cash equivalents at December 31, 2018 and December 31, 2017 , respectively, $0.0 million and $3.6 million , respectively, consisted of highly liquid investments with maturities of 90 days or less when purchased. These investments consist of investments in money market funds with commercial banks and financial institutions. As of December 31, 2018 , $147,400 of the Company’s cash and cash equivalents were held in Russian banks, of which $136,200 was denominated in rubles with the remaining $11,200 denominated in U.S. dollars.
Short-Term Investments	Short-Term Investments The Company’s short-term investments are classified as and held to maturity and recorded at amortized cost. Short-term investments consist of $0.5 million in certificates of deposit with maturity dates beyond three months and less than one year and are owned by Panacela. These investments are classified as held to maturity given the intent and ability to hold the investments to maturity. Realized gains and losses, and interest and dividends on short-term investments are recorded in our Consolidated Statement of Operations as Interest and Other Income. The cost of securities sold is based on the specific identification method.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to a significant concentration of credit risk primarily consist of cash and cash equivalents and short-term investments. The Company maintains cash balances with financial institutions in excess of insured limits.
Accounts Receivable	The Company extends unsecured credit to its government customers under normal trade agreements and contracted terms, which generally require payment within 30 days .
Equipment	Equipment Equipment is stated at cost, net of accumulated depreciation. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repair and maintenance costs are expensed as incurred.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets or related asset group may not be recoverable. Determination of recoverability is based on an estimate of discounted future cash flows resulting from the use of the asset. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the carrying amount of the asset is written down to its estimated net realizable value.
Intellectual Property	Intellectual Property Costs related to filing and pursuing patent applications are recognized as general and administrative expenses as incurred, since the recoverability of such expenditures is uncertain. Upon marketability approval by the FDA, or a respective foreign regulatory governing body, such costs will be capitalized and depreciated over the expected life of the related patent.
Accrued Warrant Liability	Accrued Warrant Liability Certain warrants are accounted for as derivative instruments in accordance with the Financial Accounting Standards Board Accounting Standards Codification (the " Codification ") on derivatives and hedging as the warrant holders, under certain change of control situations, could require settlement in cash. As such, the warrants were initially recorded as liabilities based on their fair values on the date of issuance. Subsequent changes in the value of the warrants are recorded in the Statements of Operations as "Change in value of warrant liability." The Company’s remaining outstanding warrants were treated as equity upon issuance and continue to be treated as equity since they did not contain any mandatory redemption features or other provisions that would require a different classification of these warrant instruments outside of permanent equity.
Foreign Currency Translation	Foreign Currency Translation The Russian ruble is the functional currency of our foreign subsidiaries, which are all located in the Russian Federation. Assets and liabilities of these companies are translated into U.S. dollars at the period-end exchange rate. Income and expense items are translated at the average exchange rates during the period. The net effect of this translation is recorded in the consolidated financial statements as accumulated other comprehensive income (loss).
Other Comprehensive Income/(Loss)	Other Comprehensive Income (Loss) The Company applies the Accounting Standards Codification ( "Codification" ) on comprehensive income (loss) that requires disclosure of all components of comprehensive income (loss) on an annual and interim basis. Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.
Revenue Recognition	Revenue Recognition The Company generates grant and contract revenue from two different types of contractual arrangements: cost reimbursable grants and contracts, and fixed-price grants and contracts. Costs consist primarily of internal labor charges, subcontractors and materials, as well as an allocation of fringe benefits, overhead and general and administrative expenses, based on the terms of the contract. Under cost reimbursable grants and contracts, revenue is recognized during the period that the associated research and development costs are incurred. Under fixed-price grants and contracts, revenue is recognized using the percentage-of-completion method. The assumptions and estimates used in determination of the percentage-of-completion are developed in coordination with the principal investigator performing the work.
Research and Development	Research and Development Research and development (" R&D ") costs are expensed as incurred. R&D costs primarily consist of salaries, fringe benefits, and stock-based compensation for our clinical and scientific personnel along with a ratable share of our facility expenses. Other R&D expenses include fees paid to research-oriented consultants and outside service providers, and the costs of materials used in clinical trials and other research activities.
Accounting for Stock-Based Compensation	Accounting for Stock-Based Compensation The Cleveland BioLabs, Inc. Equity Incentive Plan, adopted in 2018 (the " Plan" ), authorizes CBLI to grant (i) options to purchase common stock, (ii) restricted or unrestricted stock units, and (iii) stock appreciation rights, so long as the exercise or grant price of each are at least equal to the fair market value of the stock on the date of grant. As of December 31, 2018 , an aggregate of 597,557 shares of common stock were authorized for issuance under the Plan, of which a total of approximately 437,481 shares of common stock remained available for future awards. In addition, a total of 160,076 shares of common stock reserved for issuance were subject to currently outstanding stock options granted under the Plan, as in effect prior to the 2018 amendment and restatement. A single participant cannot be awarded more than 100,000 shares annually. Awards granted under the Plan have a contractual life of no more than 10 years . The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Plan are specified in an award document, and approved by the Company's board of directors or its management delegates. The 2013 Employee Stock Purchase Plan (" ESPP ") provides a means by which eligible employees of the Company and certain designated related corporations may be given an opportunity to purchase shares of common stock. As of December 31, 2018 , there were 525,000 shares of common stock reserved for purchase under the ESPP. The number of shares reserved for purchase under the ESPP increases on January 1 of each calendar year by the lesser of (i) 10% of the total number of shares of common stock outstanding on December 31st of the preceding year, or (ii) 100,000 shares of common stock. The ESPP allows employees to use up to 15% of their compensation to purchase shares of common stock at an amount equal to 85% of the fair market value of the Company's common stock on the offering date or the purchase date, whichever is less.
Income taxes	Income taxes No income tax expense was recorded for the years ended December 31, 2018 and 2017 as the Company did not have taxable income for any of the years presented. A full valuation allowance has been recorded against the Company’s net deferred tax asset.
Earnings (loss) per share	Earnings (Loss) per Share Basic net loss per share of common stock excludes dilution for potential common stock issuances and is computed by dividing net loss by the weighted average number of shares outstanding for the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Diluted net loss per share is identical to basic net loss per share as potentially dilutive securities have been excluded from the calculation of diluted net loss per common share because the inclusion of such securities would be antidilutive.
Recent Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ( "FASB" ) or other standard-setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. In May 2017, the FASB issued Accounting Standards Update (" ASU ") No. 2017-09, "Scope of Modification Accounting" (" ASU No. 2017-09 "), which amends the scope of modification accounting for share-based payment arrangements.The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting. ASU 2017-09 is applied prospectively to awards modified on or after the effective date. The Company adopted this ASU in 2018 with no significant impact on its consolidated financial statements. In November 2016, the FASB issued ASU 2016-18, "Statement of Cash Flows (Topic 230): Restricted Cash" (" ASU 2016-18" ). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The Company adopted this ASU in 2018 with no significant impact on its consolidated financial statements. In May 2014, the FASB issued ASU 2014-9, "Revenue from Contracts with Customers" ( "ASU 2014-09" ), which updates the principles for recognizing revenue. ASU 2014-9 also amends the required disclosures of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company adopted this ASU in 2018 with no significant impact on its consolidated financial statements. In May 2016, the FASB issued ASU 2016-12, "Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients" ( "ASU 2016-12" ). The amendments in ASU 2016-12 affect the guidance in ASU 2014-09 by clarifying certain specific aspects of the guidance, including assessment of collectability, treatment of sales taxes and contract modifications, and providing certain technical corrections. The pronouncement has the same effective date as ASU 2014-09, which is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017. The Company adopted this ASU in 2018 with no significant impact on its consolidated financial statements. In August 2016, the FASB issued ASU 2016-10, "Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing" (" ASU 2016-10" ) related to identifying performance obligations and licensing. ASU 2016-10 is meant to clarify the guidance in FASB ASU 2014-09, "Revenue from Contracts with Customers." Specifically, ASU 2016-10 addresses and entity's identification of its performance obligations in a contract, as well as an entity's evaluation of the nature of its promise to grant a license of intellectual property and whether or not that revenue is recognized over time or at a point in time. The pronouncement has the same effective date as ASU 201-09, which is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017. The Company expects to adopt this guidance when effective and is currently evaluating the effect that the updated standard will have on its consolidated balance sheets and related disclosures. The Company adopted this ASU in 2018 with no significant impact on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, "Leases (Topic 842)" (" ASU 2016-02" ). ASU 2016-02 will require organizations that lease assets with lease terms of more than 12 months to recognize assets and liabilities for the rights and obligations created by those leases on their balance sheets. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 will be effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company adopted this ASU in 2019 with no significant impact on its consolidated financial statements. In January 2016, the FASB issued ASU 2016-01, "Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities" (" ASU 2016-01" ). The pronouncement requires equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income, requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes, requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset, and eliminates the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost. The Company adopted this ASU in 2018 with no significant impact on its consolidated financial statements. Reclassification In order to facilitate comparison of financial information, certain amounts reported in the prior year have been reclassified to conform to the current year presentation.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Revenue by Customer	The following table presents our revenue by customer, on a proportional basis, for the periods indicated: Years ended December 31, 2018 2017 Variance U.S. Department of Defense 46.3 % 69.0 % (22.7 )% Incuron, LLC 53.7 % 31.0 % 22.7 % 100.0 % 100.0 % — %
Equipment Useful Lives	Equipment is depreciated using the straight-line method over the estimated useful lives of the respective assets as follows: Asset Category Estimated Useful Life (in Years) Laboratory equipment 5 Furniture and fixtures 5 Computer equipment 3
Changes in Accumulated Other Comprehensive Income (Loss)	The following table presents the changes in accumulated other comprehensive loss for the year ended December 31, 2018 . Unrealized gain (loss) on available-for-sale securities Gains and losses on foreign exchange translations Total Beginning balance $ (1,924 ) $ (514,533 ) $ (516,457 ) Other comprehensive income (loss) before reclassifications 1,924 (96,837 ) (94,913 ) Ending balance $ — $ (611,370 ) $ (611,370 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The Company has excluded the following securities from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented: As of December 31, Common Equivalent Securities 2018 2017 Warrants 528,054 710,174 Options 160,076 211,487 Total 688,130 921,661

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Hierarchy for Financial Assets and Liabilities Measured on Recurring Basis	The following tables represent the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2018 and 2017 : As of December 31, 2018 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents $ 1,130 $ — $ — $ 1,130 Short-term investments — 503,810 — 503,810 Total assets $ 1,130 $ 503,810 $ — $ 504,940 Liabilities: Accrued warrant liability $ — $ — $ 78,637 $ 78,637 As of December 31, 2017 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents $ 551,088 $ — $ — $ 551,088 Short-term investments 3,606,499 954,858 — 4,561,357 Total assets $ 4,157,587 $ 954,858 $ — $ 5,112,445 Liabilities: Accrued warrant liability $ — $ — $ 1,041,455 $ 1,041,455
Schedule of Share-Based Payment Award Warrant Liability Valuation Assumptions	The following are the assumptions used to measure the accrued warrant liability at December 31, 2018 and 2017 : "Risk-free interest rate" means the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date the option is granted. "Expected dividend yield" means the anticipated dividend return for an investor over the expected life. For the Company, this amount is zero as it is not anticipated that dividends will be paid for the foreseeable future. "Expected life" means the period of time that options granted are expected to remain outstanding, based wholly on the use of the simplified (safe harbor) method. The simplified method is used because the Company does not yet have adequate historical exercise information to estimate the expected life the options granted. "Expected volatility" means a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. Expected volatility is based on the Company’s historical volatility and incorporates the volatility of the common stock of comparable companies when the expected life of the option exceeds the Company’s trading history. December 31, 2018 2017 Stock Price $ 1.01 $ 4.01 Exercise Price $ 3.64 - 24.40 $ 3.00 - 24.40 Term in years 0.04 - 2.60 0.25 - 3.60 Volatility 88.07 - 108.18% 71.48 - 139.58% Annual rate of quarterly dividends 0 % 0 % Discount rate- bond equivalent yield 0.12 - 2.48% 0.44 - 2.05%
Summary of Changes in Fair Value of Company's Level 3 Fair Value Measurements	The following table sets forth a summary of changes in the fair value of the Company’s Level 3 fair value measurement of the accrued warrant liability for the years ended December 31, 2018 and 2017 : Year Ended December 31, 2018 Beginning Balance $ 1,041,455 Total (gains) or losses, realized and unrealized, included in earnings (1) (962,818 ) Balance at December 31, 2018 $ 78,637 Year Ended December 31, 2017 Beginning Balance $ 949,419 Total (gains) or losses, realized and unrealized, included in earnings (1) 4,426,146 Settlements (4,334,110 ) Balance at December 31, 2017 $ 1,041,455 (1) Unrealized gains or losses related to the accrued warrant liability were included as change in value of accrued warrant liability.
Summary of Unobservable Inputs in Fair Value Measurements	The following table summarizes the unobservable inputs into the fair value measurements: December 31, 2018 Description Fair Value Valuation Technique Unobservable Input Range in years Accrued warrant liability $ 78,637 Black-scholes pricing model Expected term 0.04 - 2.60

Equipment (Tables)

Equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Summary of Equipment	The following table summarizes the value of the Company’s equipment as of December 31, 2018 and 2017 : As of December 31, 2018 2017 Computer equipment $ 186,456 $ 208,943 Lab equipment 448,198 554,880 Furniture 500,201 500,202 1,134,855 1,264,025 Less accumulated depreciation (1,107,108 ) (1,245,437 ) Equipment, net $ 27,747 $ 18,588

Equity Awards (Tables)

Equity Awards (Tables)	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Schedule of Changes in Warrants Outstanding	he following table sets forth the changes in the number of warrants outstanding for the periods presented: Number of Warrants Weighted Average Exercise Price Outstanding at December 31, 2016 2,148,741 $ 11.04 Exercised (1,181,235 ) 3.64 Forfeited, Canceled (257,332 ) 50.76 Outstanding at December 31, 2017 710,174 8.95 Exercised (18,405 ) 3.00 Forfeited, Canceled (163,715 ) 3.34 Outstanding at December 31, 2018 528,054 $ 10.90
Assumptions Used to Measure the Fair Value of Warrants Exercised	The fair value of the warrants exercised was valued using the Black Scholes option pricing model based on the following assumptions: Stock Price $ 4.84 Exercise Price $ 3.64 Term in years 4.29 Volatility 101.93 % Annual rate of quarterly dividends 0 % Discount rate- bond equivalent yield 1.65 %
Summary of Option Award Activity	The following is a summary of option award activity under the Plan for the year ended December 31, 2018 : Year Ended December 31, 2018 Total Stock Options Outstanding Weighted Average Exercise Price per Share Nonvested Stock Options Weighted Average Grant Date Fair Value per Share December 31, 2017 211,487 $ 36.94 — $ — Forfeited, Canceled (51,411 ) 40.12 — — December 31, 2018 160,076 $ 35.92 — $ —
Summary of Outstanding Stock Options	The following is a summary of outstanding stock options under the Plan as of December 31, 2018 : Stock Options Outstanding Vested Stock Options Quantity 160,076 160,076 Weighted-average exercise price $ 35.92 $ 35.92 Weighted Average Remaining Contractual Term (in Years) 4.26 4.26 Intrinsic value $ — $ —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Income (Loss) from Continuing Operations before Income Tax, Domestic and Foreign	(loss) from continuing operations consists of the following: For the Year Ended December 31, 2018 2017 US operations $ (3,345,925 ) $ (9,315,082 ) Foreign operations (361,522 ) (527,590 ) $ (3,707,447 ) $ (9,842,672 )
Schedule of Deferred Tax Assets (Liabilities)	Deferred tax assets (liabilities) were comprised of the following as of the periods presented below: As of December 31, 2018 2017 Deferred tax assets: Operating loss carryforwards $ 35,706,000 $ 34,427,000 Accrued expenses 5,953,000 5,969,000 Tax credit carryforwards 3,951,000 3,864,000 Intellectual property 3,996,000 3,878,000 Equipment 110,000 150,000 Total deferred tax assets 49,716,000 48,288,000 Deferred tax liabilities: — — Net deferred tax asset 49,716,000 48,288,000 Valuation allowance (49,716,000 ) (48,288,000 ) $ — $ —
Schedule of Effective Income Tax Rate Reconciliation	The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. statutory federal income tax rate of 21% for the year ended December 31, 2018 and 34% for the year ended December 31, 2017, to the pretax loss from continuing operations as a result of the following differences: For the Year Ended December 31, 2018 2017 Tax at the U.S. statutory rate $ (779,000 ) $ (3,347,000 ) Change in value of warrant liability (202,000 ) 1,505,000 Valuation allowance 981,000 1,841,000 Other — 1,000 $ — $ —
Summary of Unrecognized Tax Benefits and the Associated Interest and Penalties	The following presents a roll-forward of the unrecognized tax benefits and the associated interest and penalties: Unrecognized Tax Benefits Interest and Penalties Balance at January 1, 2017 $ 482,000 $ — Deferred tax position 11,000 — Balance at December 31, 2017 493,000 — Deferred tax position 11,000 — Balance at December 31, 2018 $ 504,000 $ —

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments for Operating Leases	As of December 31, 2018 , future minimum payments under operating leases are as follows: 2019 $ 198,039 Total minimum lease payments $ 198,039

Description of Business (Detail

Description of Business (Detail)	Aug. 10, 2018USD ($)	Dec. 31, 2018Subsidiaryshares	Aug. 06, 2018shares	Dec. 31, 2017shares
Subsidiary or Equity Method Investee [Line Items]
Number of subsidiaries | Subsidiary		2
Common stock, issued (shares)		11,298,239		11,279,834
Payment to be exchanged for right to purchase stock, maximum | $	$ 30,000,000
Paid amount after execution of SAFE | $	$ 10,500,000
GPI
Subsidiary or Equity Method Investee [Line Items]
Ownership percentage		50.00%
Consideration For License Agreement, Assignment Of Intellectual Property, Pursuant To Contribution And Subscription Agreement | GPI
Subsidiary or Equity Method Investee [Line Items]
Common stock, issued (shares)			1,000
Everon Contributed Intellectual Property To GPI In Exchange for Shares | GPI
Subsidiary or Equity Method Investee [Line Items]
Common stock, issued (shares)			1,000
Shares Received By The Company And Everon, From GPI | GPI
Subsidiary or Equity Method Investee [Line Items]
shares received			1,000
The Company And Everon Ownership In GPI | GPI
Subsidiary or Equity Method Investee [Line Items]
Ownership interest percentage			50.00%
BioLab 612
Subsidiary or Equity Method Investee [Line Items]
Number of wholly-owned subsidiaries | Subsidiary		1

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Basis of Presentation and Consolidation (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Cash, cash equivalents, and short-term investments	$ 4,100,000
Cash restricted for use	500,000
Cash available for use	$ 3,617,234	$ 4,230,548	$ 6,901,816

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 3,617,234	$ 4,230,548	$ 6,901,816
Cash equivalents	$ 0	$ 3,600,000
Cash and highly liquid investments maturity	90 days
Russian Federation
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 147,400
Russian Rubles | Russian Federation
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	136,200
US Dollars | Russian Federation
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 11,200

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Short-Term Investments (Details) $ in Millions	Dec. 31, 2018USD ($)
Certificates of Deposit
Net Investment Income [Line Items]
Short-term investments	$ 0.5

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details) - USD ($)	Feb. 07, 2019	Dec. 31, 2018	Dec. 31, 2017
Product Information [Line Items]
Increase in cash and cash equivalents		$ (613,314)	$ (2,671,268)
Subsequent Event
Product Information [Line Items]
Increase in cash and cash equivalents	$ 8,500
Subsequent Event | Maximum
Product Information [Line Items]
Russian Ruble : Dollar Exchange Rate	$ 65.6686
Outside of the U.S. | Geographic Concentration Risk | Cash and Cash Equivalents Located Outside the US
Product Information [Line Items]
Concentration risk percentage		4.00%

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Significant Customers and Accounts Receivable (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Concentration Risk [Line Items]
Allowance for doubtful accounts receivable	$ 0.2	$ 0.2
Customer Concentration Risk | Sales Revenue, Services, Net
Concentration Risk [Line Items]
Concentration risk percentage	100.00%	100.00%
Increase (decrease) in concentration risk percentage	0.00%
Customer Concentration Risk | Sales Revenue, Services, Net | U.S. Department of Defense
Concentration Risk [Line Items]
Concentration risk percentage	46.30%	69.00%
Increase (decrease) in concentration risk percentage	(22.70%)
Customer Concentration Risk | Sales Revenue, Services, Net | Incuron, LLC
Concentration Risk [Line Items]
Concentration risk percentage	53.70%	31.00%
Increase (decrease) in concentration risk percentage	22.70%
Customer Concentration Risk | Accounts Receivable
Concentration Risk [Line Items]
Credit term	30 days

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Equipment (Detail)	12 Months Ended
	Dec. 31, 2018
Laboratory equipment
Property, Plant and Equipment [Line Items]
Estimated Useful Life (in Years)	5 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Estimated Useful Life (in Years)	5 years
Lab equipment
Property, Plant and Equipment [Line Items]
Estimated Useful Life (in Years)	3 years

Summary of Significant Accou_10

Summary of Significant Accounting Policies - Other Comprehensive Income/(Loss) (Details)	12 Months Ended
	Dec. 31, 2018USD ($)
AOCI Including Portion Attributable to Noncontrolling Interest [Abstract]
Beginning balance	$ (516,457)
Other comprehensive income (loss) before reclassifications	(94,913)
Ending balance	(611,370)
Unrealized gain (loss) on available-for-sale securities
AOCI Including Portion Attributable to Noncontrolling Interest [Abstract]
Beginning balance	(1,924)
Other comprehensive income (loss) before reclassifications	1,924
Ending balance	0
Gains and losses on foreign exchange translations
AOCI Including Portion Attributable to Noncontrolling Interest [Abstract]
Beginning balance	(514,533)
Other comprehensive income (loss) before reclassifications	(96,837)
Ending balance	$ (611,370)

Summary of Significant Accou_11

Summary of Significant Accounting Policies - Revenue Recognition (Details)	12 Months Ended
	Dec. 31, 2018Agreement
Accounting Policies [Abstract]
Number of contractual arrangement	2

Summary of Significant Accou_12

Summary of Significant Accounting Policies - Accounting for Stock-Based Compensation (Detail)	12 Months Ended
	Dec. 31, 2018shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options grants in period (in shares)	0
2006 Equity Incentive Plan (The Plan)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock authorized under 2006 Equity Incentive Plan (in shares)	597,557
Number of authorized common stock shares (in shares)	437,481
Maximum amount of shares a single participant can be awarded annually (in shares)	100,000
Contractual life of awards granted under 2006 Equity Incentive Plan	10 years
2013 ESPP Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of authorized common stock shares (in shares)	525,000
Percentage of the total number of shares of common stock outstanding of the preceding year	10.00%
Maximum amount of shares of common stock that employee can purchase per year (in shares)	100,000
Maximum percentage of annual compensation that employee can use to purchase common stock shares	15.00%
Percent of fair maket value that common stock can be purchased at	85.00%

Summary of Significant Accou_13

Summary of Significant Accounting Policies - Income taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2013
Accounting Policies [Abstract]
Income tax expense	$ 0	$ 0	$ 0

Summary of Significant Accou_14

Summary of Significant Accounting Policies - Earnings/(loss) per share (Detail) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common Equivalent Securities	688,130	921,661
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common Equivalent Securities	160,076	211,487
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common Equivalent Securities	528,054	710,174

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Liabilities:
Accrued warrant liability	$ 78,637	$ 1,041,455
Recurring
Assets:
Cash and cash equivalents	1,130	551,088
Short-term investments	503,810	4,561,357
Assets:	504,940	5,112,445
Recurring | Level 1
Assets:
Cash and cash equivalents	1,130	551,088
Short-term investments	0	3,606,499
Assets:	1,130	4,157,587
Recurring | Level 2
Assets:
Cash and cash equivalents	0	0
Short-term investments	503,810	954,858
Assets:	503,810	954,858
Recurring | Level 3
Assets:
Cash and cash equivalents	0	0
Short-term investments	0	0
Assets:	0	0
Warrants | Recurring
Liabilities:
Accrued warrant liability	78,637	1,041,455
Warrants | Recurring | Level 1
Liabilities:
Accrued warrant liability	0	0
Warrants | Recurring | Level 2
Liabilities:
Accrued warrant liability	0	0
Warrants | Recurring | Level 3
Liabilities:
Accrued warrant liability	$ 78,637	$ 1,041,455

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Share-Based Payment Award Warrant Liability Valuation Assumptions (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price (in dollars per share)	$ 1.01	$ 4.01
Annual rate of quarterly dividends	0.00%	0.00%
Minimum
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price (in dollars per share)	$ 3.64	$ 3
Term in years	3 months	3 months
Volatility	88.07%	71.48%
Discount rate-bond equivalent yield	0.12%	0.44%
Maximum
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price (in dollars per share)	$ 24.4	$ 24.4
Term in years	2 years 7 months 5 days	3 years 7 months 5 days
Volatility	108.10%	139.58%
Discount rate-bond equivalent yield	2.48%	2.05%

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Changes in Fair Value of Company's Level 3 Fair Value Measurements (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Asset and liabilities measured at fair value on nonrecurring basis	$ 0	$ 0
Accrued Warrant Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	1,041,455	949,419
Total (gains) or losses, realized and unrealized, included in earnings	(962,818)	4,426,146
Settlements		(4,334,110)
Ending balance	$ 78,637	$ 1,041,455

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Unobservable Inputs into Fair Value Measurement for Accrued Warrant Liability (Detail) - Accrued Warrant Liability - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair Value	$ 78,637	$ 1,041,455	$ 949,419
Valuation Technique	Black-scholes pricing model
Unobservable Input	Expected term
Percentage increase in expected term	10.00%
Percentage increase in warrant liability with increase in expected term	6.00%
Percentage decrease in expected term	10.00%
Percentage decrease in warrant liability with decrease in expected term	6.00%
Percentage increase in stock price	10.00%
Percentage increase in warrant liability with increase in stock price	17.00%
Percentage decrease in stock price	10.00%
Percentage decrease in warrant liability with decrease in stock price	16.00%
Minimum
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Range in years	3 months
Maximum
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Range in years	3 years 7 months 5 days

Equipment (Details)

Equipment (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	$ 1,134,855	$ 1,264,025
Less accumulated depreciation	(1,107,108)	(1,245,437)
Equipment, net	27,747	18,588
Computer equipment
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	448,198	554,880
Lab equipment
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	186,456	208,943
Furniture
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	$ 500,201	$ 500,202

Equity Awards - Schedule of Cha

Equity Awards - Schedule of Changes in Warrants Outstanding (Detail) - Warrants - $ / shares	1 Months Ended	12 Months Ended
	Apr. 30, 2017	Dec. 31, 2018	Dec. 31, 2017
Number of Warrants:
Number of Warrants Outstanding, Beginning balance (in shares)		710,174	2,148,741
Number of Warrants, Exercised (in shares)	(1,181,235)	(18,405)	(1,181,235)
Number of Warrants, Forfeited, Canceled (in shares)		(163,715)	(257,332)
Number of Warrants Outstanding, Ending balance (in shares)		528,054	710,174
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Exercise Price, Outstanding, Beginning balance (in dollars per share)		$ 8.95	$ 11.04
Weighted Average Exercise Price, Exercised (in dollars per share)		3	3.64
Weighted Average Exercise Price, Forfeited, Canceled (in dollars per share)		3.34	50.76
Weighted Average Exercise Price, Outstanding, Ending balance (in dollars per share)		$ 10.90	$ 8.95
Minimum
Class of Warrant or Right [Line Items]
Warrant expiration period		1 year
Maximum
Class of Warrant or Right [Line Items]
Warrant expiration period		7 years

Equity Awards - Fair Value of W

Equity Awards - Fair Value of Warrants Exercised Using Black Scholes Option Pricing Model (Details) - $ / shares	Apr. 20, 2017	Apr. 30, 2017	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock price (in dollars per share)			$ 1.01	$ 4.01
Expected dividend yield			0.00%	0.00%
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock Issued through cashless exercise		292,668
Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercised (in shares)		1,181,235	18,405	1,181,235
Stock price (in dollars per share)	$ 4.84
Exercise price (in dollars per share)	$ 3.64
Term in years	4 years 3 months 15 days
Expected volatility	101.93%
Expected dividend yield	0.00%
Risk-free interest rate	1.65%

Equity Awards - Summary of Opti

Equity Awards - Summary of Option Award Activity (Detail)	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Total Stock Options Outstanding:
Total Stock Options Outstanding, Beginning balance (in shares) | shares	211,487
Total Stock Options Outstanding, Forfeited, Canceled (in shares) | shares	(51,411)
Total Stock Options Outstanding, Ending balance (in shares) | shares	160,076
Weighted Average Exercise Price per Share:
Weighted Average Exercise Price per Share, Beginning balance (in dollars per share) | $ / shares	$ 36.94
Weighted Average Exercise Price per Share, Forfeited, Canceled (in dollars per share) | $ / shares	40.12
Weighted Average Exercise Price per Share, Ending balance (in dollars per share) | $ / shares	$ 35.92
Nonvested Stock Options:
Nonvested Stock Options, Beginning balance (in shares) | shares	0
Nonvested Stock Options, Forfeited, Canceled (in shares) | shares	0
Nonvested Stock Options, Ending balance (in shares) | shares	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Grant Date Fair Value per Share, Beginning balance (in dollars per share) | $ / shares	$ 0
Weighted Average Grant Date Fair Value per Share, Forfeited, Canceled (in dollars per share) | $ / shares	0
Weighted Average Grant Date Fair Value per Share, Ending balance (in dollars per share) | $ / shares	$ 0

Equity Awards - Summary of Outs

Equity Awards - Summary of Outstanding Stock Options (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options Outstanding, Quantity (in shares)	160,076	211,487
Stock Options Outstanding, Weighted-average exercise price (in dollars per share)	$ 35.92	$ 36.94
Options Additional Information:
Options grants in period (in shares)	0
Options vested in period, fair value	$ 0
Options exercised in period intrinsic value	$ 0
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options Outstanding, Quantity (in shares)	160,076
Stock Options Outstanding, Weighted-average exercise price (in dollars per share)	$ 35.92
Stock Options Outstanding, Weighted Average Remaining Contractual Term (in Years)	4 years 3 months 5 days
Stock Options Outstanding, Intrinsic value	$ 0
Nonvested Stock Options, Quantity (in shares)	160,076
Nonvested Stock Options, Weighted-average exercise price (in dollars per share)	$ 35.92
Nonvested Stock Options, Weighted Average Remaining Contractual Term (in Years)	4 years 3 months 5 days
Nonvested Stock Options, Intrinsic value	$ 0
Options Additional Information:
Options grants in period (in shares)	0	0
Compensation cost not yet recognized related to non-vested stock options	$ 0

Significant Alliances and Rel_2

Significant Alliances and Related Parties (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Related Party Transaction [Line Items]
Royalty or sublicense royalty payments, term (in years)			2 years
Research and development expense			$ 3,619,103	$ 5,048,423
R P C I
Related Party Transaction [Line Items]
Expense related to research grants and agreements			200,455	55,299
Accounts payable owed	$ 0	$ 8,391	0	8,391
Accrued expenses payable	0	84,429	0	84,429
Cleveland Clinic
Related Party Transaction [Line Items]
Accrued expenses payable	0	11,700	0	11,700
Milestone payments credited against future royalties			0
Royalty or sublicense royalty payments			0
Research and development expense			41,484	11,700
Buffalo BioLabs
Related Party Transaction [Line Items]
Accounts payable owed	28,000	0	28,000	0
Accrued expenses payable	0	13,889	0	13,889
Research and development expense			454,937	197,900
Accounts receivable related parties, gross	218,300	202,151	218,300	202,151
Accounts receivable related parties	16,149	0	16,149	0
Buffalo BioLabs | Sublease and Other Income
Related Party Transaction [Line Items]
Sublease and other income from BBL			46,212	42,361
Incuron, LLC
Related Party Transaction [Line Items]
Sublease and other income from BBL			610,907	604,010
Accounts receivable related parties, gross	33,316	158,651	33,316	158,651
Incuron, LLC | Sublease and Other Income
Related Party Transaction [Line Items]
Sublease and other income from BBL			5,107	7,104
Exacte Labs, LLC
Related Party Transaction [Line Items]
Research and development expense	$ 19,219	$ 13,719	0	$ 11,447
GPI
Related Party Transaction [Line Items]
Sublease and other income from BBL			$ 1,725

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income (Loss) from Continuing Operations before Income Tax, Domestic and Foreign (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest [Abstract]
US operations	$ (3,345,925)	$ (9,315,082)
Foreign operations	(361,522)	(527,590)
Total	$ (3,707,447)	$ (9,842,672)

Income Taxes - Additional infor

Income Taxes - Additional information (Detail) - USD ($)	Jul. 09, 2015	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Income tax expense (benefit)		$ 0	$ 0	$ 0
Operating Loss Carryforwards [Line Items]
Tax Cuts And Jobs Act, Change in Tax Rate, deferred tax assets, decrease		21,500,000
Tax Cuts And Jobs Act Of 2017, provisional income tax expense		0
Investor
Operating Loss Carryforwards [Line Items]
Stock issued during period (in shares)	6,459,948
Investor ownership percentage of company	60.20%
U.S. federal
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		144,000,000
Tax credit carryforward		4,156,000
Operating loss carryforward limitations on use		124,800,000
Tax credit carryforward limitiations on use		3,650,000
State and Local Jurisdiction
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		89,800,000
Tax credit carryforward		304,000
Operating loss carryforward limitations on use		73,400,000
Tax credit carryforward limitiations on use		324,000
Latest Tax Year | U.S. federal
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		139,700,000
No Expiration | U.S. federal
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		$ 4,300,000

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Operating loss carryforwards	$ 35,706	$ 34,427
Accrued expenses	5,953	5,969
Tax credit carryforwards	3,951	3,864
Intellectual property	3,996	3,878
Equipment	110	150
Total deferred tax assets	49,716	48,288
Deferred tax liabilities:	0	0
Net deferred tax asset	49,716	48,288
Valuation allowance	(49,716)	(48,288)
Net deferred tax asset	$ 0	$ 0

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2013
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Tax at the U.S. statutory rate	$ (779,000)	$ (3,347,000)
Change in value of warrant liability	(202,000)	1,505,000
Valuation allowance	981,000	1,841,000
Other	0	1,000
Total	$ 0	$ 0	$ 0

Income Taxes - Summary of Unrec

Income Taxes - Summary of Unrecognized Tax Benefits and the Associated Interest and Penalties (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Unrecognized Tax Benefits
Beginning balance, Unrecognized tax benefits	$ 493,000	$ 482,000
Deferred tax position	11,000	11,000
Ending balance, Unrecognized tax benefits	504,000	493,000
Interest and Penalties
Beginning balance, Interest and penalties	0	0
Deferred tax position	0	0
Ending balance at December, Interest and penalties	$ 0	$ 0

Employee Benefit Plan (Detail)

Employee Benefit Plan (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Retirement Benefits [Abstract]
Maximum percentage of employees' paycheck that company matches	4.00%
Expense relating to the Benefit Plan	$ 39,794	$ 40,962

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Oct. 22, 2018USD ($)	Oct. 22, 2018RUB (₽)	Jan. 31, 2019USD ($)	Jan. 31, 2019RUB (₽)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Loss Contingencies [Line Items]
Milestone payment & royalties					$ 0	$ 0
Unconditional purchase obligation					94,456
Operating leases, rent expense					$ 398,346	$ 401,455
MPT vs. BIo Lab 612 Breach Of 502 Contract
Loss Contingencies [Line Items]
Damages sought	$ 300,000	₽ 19,819,281
MPT VS. Bio Lab 612 Breach Of 612 Contract
Loss Contingencies [Line Items]
Damages sought	$ 750,000	₽ 49,519,600
Subsequent Event | MPT VS. Bio Lab 612 Breach Of 612 Contract
Loss Contingencies [Line Items]
Court damages awarded			$ 40,000	₽ 2,823,377

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Future Minimum Lease Payments for Operating Leases (Detail)	Dec. 31, 2018USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2,019	$ 198,039
Total minimum lease payments	$ 198,039